Novo Nordisk (NYSE:NVO): Reassessing Valuation After This Year’s Sharp Share Price Pullback
Novo Nordisk (NVO) shares have slipped over the past week and remain well below their highs this year, even though revenue and net income are still growing at mid single digit rates.
See our latest analysis for Novo Nordisk.
That recent pullback, including the 1 week share price return of minus 3.4 percent and a much steeper year to date share price return of minus 46.6 percent, shows momentum has clearly faded despite Novo Nordisk’s still growing earnings base and longer term total shareholder return remaining positive over five years.
If this volatility has you reassessing your healthcare exposure, it could be worth exploring other ideas across healthcare stocks. This can help you see how peers stack up on growth, valuation, and…
